Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
AERIE PHARMACEUTICALS INC (AERI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 05/06/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
| 11/06/2019 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Conference Call and Webcast Today, November 6th , at 5:00 p.m. ET Durham, N.C. -- -- Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2019 and provided a general business update. Aerie Third Quarter Highlights" |
|
| 08/07/2019 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Conference Call and Webcast Today, August 7th , at 5:00 p.m. ET Durham, N.C. -- -- Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2019, updated full-year 2019 guidance and provided a general business update. Aerie Second Quarter Highlights" |
|
| 05/07/2019 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update Conference Call and Webcast Today, May 7th , at 5:00 p.m. ET Durham, N.C. -- -- Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2019, along with a general business update. Aerie Highlights" |
|
| 02/25/2019 |
8-K
| Quarterly results |
| 11/06/2018 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update Conference Call and Webcast Today, November 6th , at 5:00 p.m. ET Durham, N.C. -- -- Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2018, along with a general business update. Aerie Highlights" |
|
| 05/08/2018 |
8-K
| Quarterly results |
| 02/28/2018 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results |
| 05/02/2017 |
8-K
| Form 8-K - Current report |
| 03/07/2017 |
8-K
| Form 8-K - Current report |
| 11/02/2016 |
8-K
| Form 8-K - Current report |
| 08/03/2016 |
8-K
| Form 8-K - Current report |
| 05/02/2016 |
8-K
| Form 8-K - Current report |
| 03/01/2016 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Year End 2015 Financial Results and Provides Business Update - Company on Track to File NDA in 3Q 2016 for Rhopressa TM 0.02% - Conference Call and Webcast Today, March 1, at 5:00 p.m. ET IRVINE, California - —Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and year ended December 31, 2015, along with a general business update. Aerie Highlights" |
|
| 11/03/2015 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update - Based on FDA Meetings, Company Expects to File Rhopressa TM NDA in 3Q 2016 - Conference Call and Webcast Today, November 3, at 5:00 p.m. ET IRVINE, California - —Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2015, along with a general business update. Aerie Highlights" |
|
| 08/05/2015 |
8-K
| Quarterly results |
| 05/07/2015 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Business and Strategic Update Conference Call and Webcast Today, May 7, at 5:00 p.m. ET Company to Review Additional Findings from Initial Rhopressa™ Phase 3 Registration Trial on Conference Call IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.——Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2015. The Company will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss the Company's financial results and provide a ge...",
"RhopressaTM “Rocket 1” Additional Analyses" |
|
| 03/02/2015 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business and Product Development Update Rhopressa TM Rocket 1 Efficacy Read-Out Approaching; Recent Preclinical Research Findings Represent Potential Breakthroughs Conference Call and Webcast Today, March 2, at 5:00 p.m. ET IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C, March 2, 2015 — —Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2014 and provided an update on the Company's business highlights. Aerie Highl..." |
|
| 11/12/2014 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update Focused on Building a Major Ophthalmic Pharmaceutical Company Rhopressa TM and Roclatan TM Development Programs Advancing Conference Call and Webcast Today, November 11, at 5:00 p.m. ET BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif., November 11, 2014 — — Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for third quarter 2014 and provided an update on the Company's business highlights. Aerie Highlights • Rhopressa TM Phase 3 registrat..." |
|
| 08/06/2014 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business and Product Development Update Rhopressa TM Phase 3 Registration Trials Have Commenced, Three-Month Efficacy Results Expected Mid-2015; Potential to File New Drug Application by Mid-2016 After Successful Phase 2b Results, Roclatan TM Phase 3 Enabling Activities in Progress Conference Call and Webcast Today, August 6, at 5:00 p.m. ET BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif., August 6, 2014 - - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported financial results for second quarter 2014 and provided an update on the Company's business highlight..." |
|
| 05/12/2014 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Business and Product Development Update Roclatan TM Phase 2b Clinical Trial Running Ahead of Schedule Rhopressa Phase 3 Registration Trials on Track to Begin Soon, with FDA Meetings now Completed Conference Call and Webcast Today, May 12, at 5:00 p.m. ET BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. — — Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported financial results for first quarter 2014 and provided an update on the Company's business highlights. Aerie Highlights • The Roclatan TM Phase 2b clinical trial is advancing rapidly, with public release of ...",
"Company Overview presentation" |
|
| 03/18/2014 |
8-K
| Quarterly results|
Docs:
|
"Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business and Product Development Update Aerie on Track with Both Clinical Programs; Debuts Product Trade Names for Triple-Action and Quadruple-Action Candidates Conference Call and Webcast Today, March 18, at 5:00 p.m. ET BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif., March 18, 2014 ——Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business highlights. Aerie Highlights" |
|
| 12/04/2013 |
8-K
| Form 8-K - Current report |
|
|